TCM
IMVT icon

Tekla Capital Management’s Immunovant IMVT Stock Holding History

Tekla Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$6.38M Buy
336,200
+220,800
+191% +$4.12M 0.25% 76
2023
Q1 		$1.79M Buy
+115,400
New +$2M 0.07% 124

Other funds holding IMVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Tekla Capital Management's IMVT Position: Q2 2023 in Review

Tekla Capital Management increased its Immunovant (IMVT) stake by 191% in Q2 2023, buying an estimated $4.12M and bringing the position to 336,200 shares worth $6.38M. The position accounts for 0.25% of the portfolio, ranked #76.

Tekla Capital Management first reported a position in IMVT in Q1 2023 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold IMVT as of Q2 2023.

  • Tekla Capital Management held 336,200 shares of Immunovant worth $6.38M as of Q2 2023.
  • Tekla Capital Management bought 220,800 Immunovant shares in Q2 2023, an estimated $4.12M.
  • Immunovant made up 0.25% of Tekla Capital Management's portfolio in Q2 2023, its #76 holding.
  • Tekla Capital Management first reported a position in Immunovant in Q1 2023 and has held it in 2 quarters since.
  • 147 funds tracked by Wall St. Rank held Immunovant as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.